TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01054599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: All subjects in the treatment group will be placed on memantine. The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the first phase of the study. At the conclusion of the first 13 weeks, subjects will discontinue the treatment (memantine or placebo) and enter the open label phase.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: In the control arm of the study, subjects will take one placebo sugar pill per day for one week, then increase to one tablet twice per day for the following 12 weeks. At the end of this phase of the study, subjects will enter the open-label phase (unblinded treatment with memantine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Open label: When the blinded phase is complete (Weeks 1-13), all subjects will receive open-label treatment with memantine (Weeks 14-26). The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the study. At the conclusion of the study, subjects will discontinue the treatment.
Study: NCT04204577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Evaluation of the efficacy and safety of simple local ablation, local ablation combined with apatinib, local ablation combined with apatinib and PD-1 antibody SHR-1210 for advanced liver cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Evaluation of the efficacy and safety of simple local ablation, local ablation combined with apatinib, local ablation combined with apatinib and PD-1 antibody SHR-1210 for advanced liver cancer.
Study: NCT00775697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: the arm will be treated with Montelukast 4 mg die for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: montelukast 4 mg day for 4 weeks
Study: NCT01326403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: GROUP A - receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.~GROUP B - IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.~Group C - A control group will only receive placebo in the emergency room and in the OR.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid
Description: GROUP A - receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.~GROUP B - IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.~Group C - A control group will only receive placebo in the emergency room and in the OR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: GROUP A - receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.~GROUP B - IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.~Group C - A control group will only receive placebo in the emergency room and in the OR.
Study: NCT00995137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Cell Infusion
Description: Infusing genetically modified NK cells into research participants who have chemotherapy refractory or relapse B-lineage ALL.
Study: NCT04305964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nastent® (a distally perforated soft silicon nasal tube)
Description: Insertion of the Nastent® to nostril during sleep hours

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polygraphy with WatchPAT™ 300
Description: WatchPAT™ 300 is an innovative diagnostic Home Sleep Apnea Test (HSAT) that utilizes the proprietary Peripheral Arterial Tone signal (PAT™) to enable simple, accurate and reliable sleep apnea testing.
Study: NCT01315145

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Lumbar Decompression
Description: The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Steroid Injection
Description: Injection of epidural steroids into the lumbar spine
Study: NCT03516383

Intervention type: DEVICE
Intervention: PWVi

Intervention type: DEVICE
Intervention: PWVi
Study: NCT02156648

Intervention type: OTHER
Group type: OTHER
Intervention: Feasibility study
Description: All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5.
Study: NCT05777213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secretome
Description: The interventions given in this study were Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs) as much as 0.1cc / 1cm intracutaneously with a flexpen device in the wound area every 2 weeks. The variables in this study were divided into two, namely the independent variable was the use of Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs) were administered intracutaneously, and the dependent variables were wound healing and side effects caused by the interventions given. Wound healing or repair in this study was assessed from several variables, namely the presence of granulation tissue growth, reduced edema, reduced erythema and improvement in wound size both in terms of length, width, and area measured by using a standard ruler and digital photo.
Study: NCT02876445

Intervention type: OTHER
Group type: OTHER
Intervention: ZARIT Burden Interview
Description: ZARIT Burden Interview completed Day 0 and 1 year
Study: NCT00643292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin/clavulanate postassium (Augmentin ES-600)
Description: amoxicillin/clavulanate postassium 90/6.4 mg/kg/day, given in divided doses q12h, for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin SR
Description: azithromycin SR 60 mg/kg x 1 dose
Study: NCT02551653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]-GSK2256098 500 MBq
Description: \[11C\]-GSK2256098 injection will be provided as IV infusion, 20 mL, containing up to 5% ethanol in saline.
Study: NCT03660748

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MET-2
Description: Ingestion of a novel human microbiome preparation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MET-2
Description: Ingestion of a novel human microbiome preparation
Study: NCT03533231

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Canal Disinfection Triple Antibiotic Paste (TAP)
Description: Patients were treated as follows: Caries was excavated; access cavity was prepared. The rubber dam was then applied and working length was determined. Canal space was irrigated using 40 cc of NaOCl 2.6% solution and final flush of saline. Canal space was dried using paper points. One cc of the prepared paste was injected into the canals using a sterile plastic syringe with 20 gauge needle. The access cavity was then sealed using temporary restoration. After the 3 weeks, anesthesia without vasoconstrictor was administrated. The antibiotic paste was removed and the canal was irrigated using a sterile saline and dried using paper points. Sterile hand file size #25 was introduced into the root canal beyond the working length to induce bleeding. The bleeding was allowed to reach a 3-mm level below the cemento-enamel junction. MTA was used to seal the root canal at the cervical level. After one week, adhesive composite resin was used to seal the access cavity.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin + Propolis Paste

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin + Metronidazole Paste

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Propolis + Metronidazole paste
Study: NCT04383197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance exercise training
Description: Ergometer cycling at 70 % of VO2 max, 45 minutes, 3 times a week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance exercise training
Description: Ergometer cycling at 70 % of VO2 max, 45 minutes, 3 times a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: 3 months of therapeutic treatment with semaglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: 3 months of therapeutic treatment with semaglutide
Study: NCT02541331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISMIGEN
Description: Tablets of 30 billion organisms/mg - Sublingual use 1 tablet per day over 10 days for 3 successive months.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Matched tablets without any active substance.
Study: NCT00458003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: Ephedrine concentration: 8 mg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP \> 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP \< 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine concentration: 100 mcg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP \> 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP \< 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.
Study: NCT02931760

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous pacemaker
Description: During implant of a pacemaker the device is either implanted subcutaneously or intramuscular

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intramuscular pacemaker
Description: During implant of a pacemaker the device is either implanted subcutaneously or intramuscular
Study: NCT00857662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Onyx
Description: Embolization

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRUFILL
Description: Embolization
Study: NCT02085200

Intervention type: OTHER
Group type: OTHER
Intervention: horizontal adduction stretch with scapular stabilization
Description: Scapular is stabilized during manual horizontal adduction stretch

Intervention type: OTHER
Group type: OTHER
Intervention: Horizontal adduction stretch without scapular stabilization
Description: Scapula stabilization is not performed during horizontal adduction stretch
Study: NCT03248869

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current Daily Survey
Description: need description

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health App
Description: Participants recruited, consented and enrolled via the AMHA and complete assessments using the app
Study: NCT01001910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study: NCT00756626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bottle Weaning Intervention
Description: WIC Nutritionist will deliver bottle weaning intervention education with participants in intervention group at 12 month baseline and at 15, 18, 21, and 24 month follow-up as needed
Study: NCT04426942

Intervention type: OTHER
Intervention: survey
Description: survey on sexuality during pregnancy

Intervention type: OTHER
Intervention: survey
Description: survey on sexuality during pregnancy
Study: NCT02644278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-984 120 mg + PLD 40 mg/m^2
Description: Participants received VX-984 orally 120 milligram (mg) orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 120 mg in combination with pegylated liposomal doxorubicin (PLD) 40 milligram per square meter (mg/m\^2) administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-984 240 mg + PLD 40 mg/m^2
Description: Participants received VX-984 orally 240 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 240 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
Study: NCT04324723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp message
Description: The experimentally evaluated part of the intervention is a WhatsApp message.~The message translated from Arabic to English appears below. Dear \[First name\], Your BP reading during Beirut Marathon was \[reading\]. This indicates that you have elevated blood pressure. You should seek medical attention at your earliest convenience. Your wellbeing matters to us. Nudge Lebanon team
Study: NCT02644278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-984 480 mg + PLD 40 mg/m^2
Description: Participants received VX-984 orally 480 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 480 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-984 720 mg + PLD 40 mg/m^2
Description: Participants received VX-984 orally 720 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 720 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
Study: NCT03933163

Intervention type: DRUG
Group type: OTHER
Intervention: Resveratrol
Description: Drug name: Micronised resveratrol. Dosage form: 500mg capsules. Alternate name: 1,3-Benzenediol, 5-\[2-(4-hydroxyphenyl)ethenyl\]-, (E). Ingredients: 99.50% pure trans-resveratrol. Placebo capsules will be identical in terms of taste, smell, and appearance.

Intervention type: DRUG
Group type: OTHER
Intervention: Resveratrol
Description: Drug name: Micronised resveratrol. Dosage form: 500mg capsules. Alternate name: 1,3-Benzenediol, 5-\[2-(4-hydroxyphenyl)ethenyl\]-, (E). Ingredients: 99.50% pure trans-resveratrol. Placebo capsules will be identical in terms of taste, smell, and appearance.
Study: NCT03073486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olumacostat Glasaretil Gel, 5.0%
Description: Gel containing Olumacostat Glasaretil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olumacostat Glasaretil Gel, Vehicle
Description: Vehicle (placebo) gel
Study: NCT01262144

Intervention type: RADIATION
Intervention: Radiotherapy
Description: Radiotherapy for cervical cancer
Study: NCT05580484

Intervention type: PROCEDURE
Intervention: Second surgery
Description: The primary outcomes were adhesion severity and adhesion area in the lower ab-dominal cavity, as determined through direct visual observation of a laparotomy wound or laparoscopic observation from stoma closure wound.
Study: NCT01918501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood testing
Description: Blood sample will be taken once from 120 volunteers. The blood will be examine in a blind fashion, including 60 MS patients diagnosed by a neurologist based on clinical and MRI findings. The control group will include 50 age and gender match healthy volunteers and 10 more patients with unrelated neurological diseases
Study: NCT00447772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Active Drug: Botulinum type A toxin (Dysport®) 500 Units / 2.5 ml injected in muscles involved in cervical dystonia
Study: NCT03011866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wound topically irrigated with 500mg TXA

Intervention type: DRUG
Group type: OTHER
Intervention: 1mg/kg/hr TXA intravenous infusion till the last suture
Study: NCT02996071

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sleeve gastrectomy
Description: a sleeve gastrectomy operation that is performed laparoscopically.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sleeve gastrectomy
Description: a sleeve gastrectomy operation that is performed laparoscopically.
Study: NCT03884335

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic radical prostatectomy
Description: The surgery was carried out by laparoscopy. Intraoperative anesthetic maintenance was performed with TCI of propofol infusion for bispectral index between 40 and 60, restrictive administration of fluids or goal-directed parenteral fluid administration, normothermia, normotension and optimal intraoperative analgesia were maintained following the criteria of ERP. Afterwards, patients were awoken from general anaesthesia and transferred to the post-anaesthesia care unit (PACU) for a 6-hour follow-up prior to transfer to conventional ward.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic radical prostatectomy
Description: The surgery was carried out by laparoscopy. Intraoperative anesthetic maintenance was performed with TCI of propofol infusion for bispectral index between 40 and 60, restrictive administration of fluids or goal-directed parenteral fluid administration, normothermia, normotension and optimal intraoperative analgesia were maintained following the criteria of ERP. Afterwards, patients were awoken from general anaesthesia and transferred to the post-anaesthesia care unit (PACU) for a 6-hour follow-up prior to transfer to conventional ward.
Study: NCT04039373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986256
Description: specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: specified dose on specified days
Study: NCT00227942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen Replacement Therapy
Description: 17-b-Estradiol Patch, .05 mg/day; applied for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: 10 mg/day, po qhs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01371292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transformational Teaching
Description: Physical education teachers randomly assigned to the experimental condition will (through a 1-day workshop format) be provided with the resources to implement transformational approaches in their day-to-day work. In addition, these teachers will be involved in a follow-up support program following the workshop to help them to implement transformational teaching strategies that were developed in the workshop.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Educational Practices
Description: Physical education teachers randomly assigned to the control condition will take part in a professional development day workshop provided by their respective School Board. This will involve the same amount of contact time, and will take place on the same day as the transformational teaching workshop. It should be noted that the focus of those alternative workshops is unrelated to transformational leadership training.
Study: NCT04406506

Intervention type: DEVICE
Intervention: nasogastric
Description: • The insertion of NG tubes were performed by the ICU physician and the position was checked by auscultation of gas from 50 ml syringe by injecting 20 ml of air in the NG and by X-ray abdomen to be sure from the site of NG tube

Intervention type: DEVICE
Intervention: nasojejunal
Description: * The nasojejunal tube is silicone or polyurethane tube with an inner stylet that is positioned (under fluoroscopic guidance) beyond the ligament of Treitz.~* Patients were placed in right lateral position

Intervention type: DRUG
Intervention: (erythromycin 250 mg IV bolus)
Description: prokinetic (erythromycin 250 mg IV bolus) given to assist the passage of the tube through the pylorus

Intervention type: DRUG
Intervention: (erythromycin 250 mg IV bolus)
Description: prokinetic (erythromycin 250 mg IV bolus) given to assist the passage of the tube through the pylorus
Study: NCT00056277

Intervention type: DRUG
Group type: OTHER
Intervention: lamotrigine
Study: NCT04037657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: HSK3486 was administered as a single dose over a 1 minute infusion period. There were five cohorts of six subjects per cohort (5 HSK3486:1 propofol).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol, at a dose of 2.5 mg/kg, was administered as a 1 minute infusion at a constant rate via infusion pump.